A new study shows that the vast majority of high-risk women are not taking tamoxifen to prevent breast cancer, even though tamoxifen is very effective for just this problem.
WSJ and others report today on the new FDA approval for Crestor.
From the article:
"The FDA just expanded the drug’s approval to include reducing the risk of heart attack and stroke in people who meet all of the following criteria:
A new study has found that cholesterol medicines known as "statins" may reduce the risk of strokes heart attacks and death by almost half when studied in patients with normal levels of cholesterol. With this finding at least 32 million people would be eligible for treatment. The drug studied is AstraZeneca Plc’s Crestor. The patients eligible for the study are those who have high amounts of a protein linked to inflammation.